Skip to main content

Utilization of Hormonal Contraceptives During the Postpartum Period in the FDA Sentinel System

Basic Details
Date
Type
Presentation
Description

Hormonal contraceptive (HC) use during the postpartum period may elevate venous thromboembolism (VTE) risk, especially with combined hormonal contraceptives (CHCs). This study examined utilization patterns of HC initiation in the postpartum period among women in the U.S. FDA Sentinel System from 2012 through 2024. This poster was presented at the 2025 ISPE Annual Meeting.

Materials

Utilization of Hormonal Contraceptives During the Postpartum Period in the FDA Sentinel System

Information
Host

International Society for Pharmacoepidemiology

 

Related Assessment(s)
Individual Drug Study: Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis
2025 ISPE Annual Meeting
Presenter(s)

Bahareh Rasouli

Author(s)

Keewan Kim, Bahareh Rasouli, Anandi Kotak, Rebecca Hawrusik, Megan Wiley, Nora P McElroy, Audrey Gassman, José J. Hernández-Muñoz, Jummai Apata, Natasha Pratt, Adebola Ajao, Mayura Shinde